FDA gives Bard marketing approval for endovascular stent graft
C. R. Bard has received approval from the FDA to market the Flair endovascular stent graft with an optimized delivery system.
The company said that its Flair graft is indicated to treat stenoses in synthetic arteriovenous bypass grafts. The device, comprised of a self-expanding Nitinol stent encapsulated within Bard’s proprietary ePTFE graft material, is marketed by the Bard Peripheral Vascular Division located in Tempe, Ariz.
Timothy M. Ring, chairman and CEO, said that the approval is the first step for the company in developing its position in the U.S. peripheral vascular stent market.
The company said that its Flair graft is indicated to treat stenoses in synthetic arteriovenous bypass grafts. The device, comprised of a self-expanding Nitinol stent encapsulated within Bard’s proprietary ePTFE graft material, is marketed by the Bard Peripheral Vascular Division located in Tempe, Ariz.
Timothy M. Ring, chairman and CEO, said that the approval is the first step for the company in developing its position in the U.S. peripheral vascular stent market.